Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume

Conditions: Urothelial Carcinoma Bladder, Sperm Count, Low, Testis; Fibrosis

Sex: Male

Ages: 20 Years – 60 Years

Phase: PHASE4

Enrollment: 25

Sponsor: Assiut University

Summary

To evaluate the effects of local intravesical B.C.G and gemcitabine on semen quality and testicular volume.

Eligibility Criteria

Inclusion Criteria:Male patients from 20 to 60's year old (the years of reproductive active men)Non muscle invasive bladder (T1 or less) urothelial carcinoma who are elected to intravesical immunotherapy or chemotherapy after TURTExclusion Criteria:i. T1 carcinomas of bladder in which intravesical immunotherapy and chemotherapy is contraindicated ii. Patients under conditions that may affect sperm number, e.g. Systemic chemotherapy, radiotherapy and previous history of genitourinary tuberculosis, Prostatic carcinoma,…etc iii. Abnormal semen parameters or abnormal hormonal profile (hypogonadism) that interfere with the study, especially azoospermia and aspermia

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05701332). StuddyBuddy aggregates publicly available trial information.